

TB Alliance Portfolio

Discovery			Preclinical Development	Clinical Development		
TARGET OR CELL-BASED SCREENING	LEAD IDENTIFICATION	LEAD OPTIMIZATION		CLINICAL PHASE I	CLINICAL PHASE II	CLINICAL PHASE III
Natural Products IMCAS	Whole-Cell Hit to Lead Program GSK	Mycobacterial Gyrase Inhibitors GSK	TBA-354 U. of Auckland/ U. Ill Chicago		PA-824 Novartis	Moxifloxacin (+ H, R, Z) Bayer
TB Drug Discovery Portfolio NITD		THPP Series GSK	Preclinical TB Regimen Development JHU/U. Ill Chicago		TMC207 Tibotec	Moxifloxacin (+ R, Z, E) Bayer
Topoisomerase I Inhibitors AZ/NYMC	Gyrase B Inhibitors AZ	Pyrazinamide Analogs Yonsei			PA-824/Pyrazinamide	
	Folate Biosynthesis Inhibitors AZ	Diarylquinolines Tibotec/U. of Auckland			TMC207/Pyrazinamide	
	Whole-Cell Hit to Lead Program AZ	Riminophenazines IMM/BTTTRI			PA-824/TMC207	
	RNA Polymerase Inhibitors AZ				PA-824/ Moxifloxacin/ Pyrazinamide	
	Energy Metabolism Inhibitors AZ/U. Penn					

■ Novel TB regimen development

Current first-line TB treatment consists of:
isoniazid (H) +
rifampicin (R) +
pyrazinamide (Z) +
ethambutol (E)

